#EHA2024: Chronic lymphocytic leukemia and small lymphocytic lymphoma

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to chronic lymphocytic leukemia and small lymphocytic lymphoma, here.

CONGRESS #EHA2024 | @NitinJainMD @MDAndersonNews reports results of the phase 2 trial of pirtobrutinib, venetoclax & obinutuzumab in first-line treatment of pts with CLL. N=40, mFU=11.7 mo, 6 mo uMRD was 64% (PB=79%), 12-mo uMRD was 85% (PB=90%). Safety profile was similar to the… pic.twitter.com/b6fyC82jWr

— Lymphoma Hub (@lymphomahub) June 14, 2024

CONGRESS #EHA2024 | Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo,… pic.twitter.com/7KJqjY1zBS

— Lymphoma Hub (@lymphomahub) June 14, 2024

CONGRESS #EHA2024 | Paolo Ghia @MyUniSR reports preliminary results from the Arm D of phase 3 SEQUOIA trial of zanubrutinib + venetoclax in treatment-naive CLL/SLL with del(17P) and/or TP53. N=66, mFU 31.6 mo, ORR=100%, CR+CRi=48%, uMRD was achieved by 59% pts in ≥1 PB sample,… pic.twitter.com/G9YwrrZOuS

— Lymphoma Hub (@lymphomahub) June 14, 2024

CONGRESS #EHA2024 | Kerry Rogers at the Ohio State University reports 7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL. N=75, mFU=27.9 mo, uMRD status was achieved in 44%, 52%, 60% of RR, TN1, TN2 pts resp. mPFS was 81.8 mo, 88.5… pic.twitter.com/5a10ahJvnI

— Lymphoma Hub (@lymphomahub) June 14, 2024

CONGRESS #EHA2024 | Poster | Santiago Ossorio Prendes at hospital universitario gregorio marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. N=8, projected proportion of… pic.twitter.com/TgG5PRGsv9

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS #EHA2024 | Poster | Jennifer R. Brown @DanaFarber reports patients reported outcomes of ALPINE study of zanubrutinib vs ibrutinib in R/R CLL/SLL. In the PFS model, zanubrutinib shown statistically significant reduction in the risk of investigator-assessed PFS events vs… pic.twitter.com/a84EQllf4m

— Lymphoma Hub (@lymphomahub) June 15, 2024

CONGRESS | #EHA2024
William Wierda @wwierda @MDAndersonNews presents exploratory analyses from TRANSEND CLL 004 trial in heavily pre-treated patients with R/R #CLL/#SLL (median 5 prior lines of therapy).
▪️ Lower baseline disease burden was associated with achievement of… pic.twitter.com/OitNReB1u8

— Lymphoma Hub (@lymphomahub) June 16, 2024

CONGRESS #EHA2024 | Poster | Jan Burger @MDAndersonNews reports phase 2 study of time-limited treatment with acalabrutinib plus obinutuzumab in pts with treatment-naïve CLL. N=28, estimated 2 yr PFS & OS were 95.8%. ORR=100%, CR=67%, PR=33% at end of therapy. BM infiltration by… pic.twitter.com/hBJiEE4ELA

— Lymphoma Hub (@lymphomahub) June 15, 2024